Medical technology giant Becton Dickinson & Co. (NYSE:BDX) is still navigating choppy waters in the 3rd quarter, posting a strong sales but taking a hit its bottom line due, in part, to a $22 million class action lawsuit and continued device tax woes.
Wall Street Beat
Masimo shares jump on Q2 earnings
Wall Street smiled on Masimo (NSDQ:MASI) yesterday with an 11% boost share prices in morning trading, which settled down to a 6.3% bump by the end of the day.
The California medical device maker gained strong favor after reporting strong sales and per-share earnings that beat analysts’ consensus estimates.
LeMaitre doesn’t win much Wall Street favor with record sales in Q2
LeMaitre Vascular (NSDQ:LMAT) posted an 8% bump in profits for its 2nd quarter and raised guidance estimates for the year, but Wall Street was less than enthused.
Hospira bounces back in Q2, gains Wall Street’s favor
Weight loss: EnteroMedics’ losses widen as company seeks FDA approval
Teleflex holds steady after beating Wall Street’s expectations
Hansen Medical pulls in $93M, shares surge 20% | Wall Street Beat
Hansen Medical (NSDQ:HNSN) said it inked an equity financing deal for up to $93 million with a consortium of investors including Oracle Investment Management and private equity player Jack Schuler, a co-founder of Crabtree Partners.
Drama at Siemens: Rumors fly that outgoing CEO is looking to take chairman down with him
Greatbatch raises guidance on Q2 figures
Texas medical device maker Greatbatch (NYSE:GB) posted a profit in Q2 and nudged its 2013 per-share earnings guidance up for the 2nd time in 2 months. The device maker’s Q2’s sales eked out a 3% boost over last year’s figures and profits were up 10%, according to the financial release.
Haemonetics swings to Q1 red, lowers full-year guidance; Wall Street flees
Haemonetics Corp. (NYSE:HAE) took a Wall Street dip after posting a hard swing to the red and adjusted per-share earnings just shy of analysts’ expectations.
Intuitive Surgical boosts share buyback plan, to repurchase $500M worth from Goldman Sachs
Intuitive Surgical (NSDQ:ISRG) said its board OK’s an additional $779 million worth of share repurchasing, including a planned $500 million buyback from Goldman Sachs.